Scholarlink

Purpose <p>This study evaluated the measurement properties and ability to detect clinically meaningful change of the Mastocytosis Symptom Severity Daily Diary (MS2D2), a patient-reported outcome instrument designed to measure symptom severity in adults with nonadvanced systemic mastocytosis (NonAdvSM).</p> Methods <p>Psychometric evaluation of the MS2D2 used blinded data from 230 adults with NonAdvSM enrolled in the Summit Phase 2 study (NCT05186753). The study comprised two parts: Part 1 (n = 54) for dose-finding and initial domain structure development, and Part 2 (n = 179) for efficacy evaluation, validation and longitudinal assessment. Analyses included item-level statistics, confirmatory factor analysis (CFA), internal consistency (Cronbach’s α), test–retest reliability (ICC), convergent and known-groups validity, responsiveness, and anchor-based estimation of meaningful change thresholds.</p> Results <p>Structural validity supported a four-domain, 11-item Total Symptom Score (TSS) framework. Internal consistency and test–retest reliability were excellent (α = 0.79–0.95; ICC = 0.95–0.98). Convergent validity was supported through strong correlations with disease-specific symptom and health-related quality of life (HRQoL) measures (r = 0.85 and r = 0.59). Known-groups validation revealed domain scores differing by 2–5 points between anchor severity strata and TSS by 2.8 points (all <i>p</i> &lt; 0.05). Scores were sensitive to change, correlating (r = 0.39–0.74) with changes in patient status. TSS within-patient meaningful improvement thresholds were 1.6–2.2 points (0–10 scale) and 17.2–24.7 points (0–110 sum), with domains showing similar ranges. Percent change thresholds indicated meaningful improvement at approximately 30–40% reduction for both TSS and domain scores.</p> Conclusions <p>MS2D2 is a reliable, valid, and responsive instrument for assessing symptom severity in NonAdvSM, with evidence supporting its use in clinical trials to evaluate treatment benefit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Psychometric evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) in adults with nonadvanced systemic mastocytosis (NonAdvSM)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • James C. Marcus,
  • Cem Akin,
  • Jenna Zhang,
  • Rachael Easton,
  • Michelle Lim-Watson,
  • Frank Siebenhaar,
  • Chad Gwaltney,
  • Ralph Turner

摘要

Purpose

This study evaluated the measurement properties and ability to detect clinically meaningful change of the Mastocytosis Symptom Severity Daily Diary (MS2D2), a patient-reported outcome instrument designed to measure symptom severity in adults with nonadvanced systemic mastocytosis (NonAdvSM).

Methods

Psychometric evaluation of the MS2D2 used blinded data from 230 adults with NonAdvSM enrolled in the Summit Phase 2 study (NCT05186753). The study comprised two parts: Part 1 (n = 54) for dose-finding and initial domain structure development, and Part 2 (n = 179) for efficacy evaluation, validation and longitudinal assessment. Analyses included item-level statistics, confirmatory factor analysis (CFA), internal consistency (Cronbach’s α), test–retest reliability (ICC), convergent and known-groups validity, responsiveness, and anchor-based estimation of meaningful change thresholds.

Results

Structural validity supported a four-domain, 11-item Total Symptom Score (TSS) framework. Internal consistency and test–retest reliability were excellent (α = 0.79–0.95; ICC = 0.95–0.98). Convergent validity was supported through strong correlations with disease-specific symptom and health-related quality of life (HRQoL) measures (r = 0.85 and r = 0.59). Known-groups validation revealed domain scores differing by 2–5 points between anchor severity strata and TSS by 2.8 points (all p < 0.05). Scores were sensitive to change, correlating (r = 0.39–0.74) with changes in patient status. TSS within-patient meaningful improvement thresholds were 1.6–2.2 points (0–10 scale) and 17.2–24.7 points (0–110 sum), with domains showing similar ranges. Percent change thresholds indicated meaningful improvement at approximately 30–40% reduction for both TSS and domain scores.

Conclusions

MS2D2 is a reliable, valid, and responsive instrument for assessing symptom severity in NonAdvSM, with evidence supporting its use in clinical trials to evaluate treatment benefit.